These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 28727741)

  • 1. Antimicrobial resistance rates in gram-positive bacteria do not drive glycopeptides use.
    Gladstone BP; Cona A; Shamsrizi P; Vilken T; Kern WV; Malek N; Tacconelli E
    PLoS One; 2017; 12(7):e0181358. PubMed ID: 28727741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiology and risk factors of methicillin-resistant
    Huang L; Zhang R; Hu Y; Zhou H; Cao J; Lv H; Chen S; Ding S; Chen G
    Antimicrob Resist Infect Control; 2019; 8():90. PubMed ID: 31164979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between antimicrobial consumption and resistance among Staphylococcus aureus and enterococci causing healthcare-associated infections at a university hospital in Taiwan from 2000 to 2009.
    Lai CC; Wang CY; Chu CC; Tan CK; Lu CL; Lee YL; Huang YT; Lee PI; Hsueh PR
    Eur J Clin Microbiol Infect Dis; 2011 Feb; 30(2):265-71. PubMed ID: 20953652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial resistance trends in bloodstream infections at a large teaching hospital in China: a 20-year surveillance study (1998-2017).
    Tian L; Zhang Z; Sun Z
    Antimicrob Resist Infect Control; 2019; 8():86. PubMed ID: 31161033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between antimicrobial consumption and incidence of health-care-associated infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci at a university hospital in Taiwan from 2000 to 2010.
    Lai CC; Chu CC; Cheng A; Huang YT; Hsueh PR
    J Microbiol Immunol Infect; 2015 Aug; 48(4):431-6. PubMed ID: 24388582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrobial resistance trends among 5608 clinical Gram-positive isolates in China: results from the Gram-Positive Cocci Resistance Surveillance program (2005-2010).
    Zhao C; Sun H; Wang H; Liu Y; Hu B; Yu Y; Sun Z; Chu Y; Cao B; Liao K; Lei J; Hu Z; Zhang L; Zhang X; Xu Y; Wang Z; Chen M
    Diagn Microbiol Infect Dis; 2012 Jun; 73(2):174-81. PubMed ID: 22521693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
    Smith JR; Yim J; Raut A; Rybak MJ
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2352-8. PubMed ID: 26833159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging issues in the diagnosis and management of infections caused by multi-drug-resistant, gram-positive cocci.
    Napolitano LM
    Surg Infect (Larchmt); 2005; 6 Suppl 2():S-5-22. PubMed ID: 23577494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular characteristics and predictors of mortality among Gram-positive bacteria isolated from bloodstream infections in critically ill patients during a 5-year period (2012-2016).
    Papadimitriou-Olivgeris M; Kolonitsiou F; Karamouzos V; Tsilipounidaki K; Nikolopoulou A; Fligou F; Marangos M; Petinaki E; Spiliopoulou I
    Eur J Clin Microbiol Infect Dis; 2020 May; 39(5):863-869. PubMed ID: 31898796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of novel glycopeptides versus vancomycin for the treatment of gram-positive bacterial infections including methicillin resistant Staphylococcus aureus: A systematic review and meta-analysis.
    Jame W; Basgut B; Abdi A
    PLoS One; 2021; 16(11):e0260539. PubMed ID: 34843561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial resistance in Europe and its potential impact on empirical therapy.
    Rossolini GM; Mantengoli E
    Clin Microbiol Infect; 2008 Dec; 14 Suppl 6():2-8. PubMed ID: 19040461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on activity of dalbavancin and comparators against clinical isolates of Gram-positive pathogens from Europe and Russia (2017-2018), and on clonal distribution of MRSA.
    Riccobono E; Giani T; Baldi G; Arcangeli S; Antonelli A; Tellone V; Del Vecchio A; De Joannon AC; Rossolini GM
    Int J Antimicrob Agents; 2022 Feb; 59(2):106503. PubMed ID: 34929289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of the COVID-19 pandemic on pediatric bloodstream infections and alteration in antimicrobial resistance phenotypes in Gram-positive bacteria, 2020-2022.
    Fallah F; Karimi A; Azimi L; Ghandchi G; Gholinejad Z; Abdollahi N; Oskooie NA; Khodaei H; Armin S; Behzad A; Hashemi SM; Ahmadizadeh SN; Alebouyeh M
    BMC Pediatr; 2024 Oct; 24(1):671. PubMed ID: 39425109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Literature review on the distribution characteristics and antimicrobial resistance of bacterial pathogens in neonatal sepsis.
    Wang J; Zhang H; Yan J; Zhang T
    J Matern Fetal Neonatal Med; 2022 Mar; 35(5):861-870. PubMed ID: 32102584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci and β-haemolytic streptococci collected from western European countries in 2011.
    Morrissey I; Seifert H; Canton R; Nordmann P; Stefani S; Macgowan A; Janes R; Knight D;
    J Antimicrob Chemother; 2013 Jan; 68(1):164-7. PubMed ID: 22941898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nosocomial infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci at a university hospital in Taiwan from 1991 to 2003: resistance trends, antibiotic usage and in vitro activities of newer antimicrobial agents.
    Hsueh PR; Chen WH; Teng LJ; Luh KT
    Int J Antimicrob Agents; 2005 Jul; 26(1):43-9. PubMed ID: 15975769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gram-Positive Bacterial Infections: Research Priorities, Accomplishments, and Future Directions of the Antibacterial Resistance Leadership Group.
    Doernberg SB; Lodise TP; Thaden JT; Munita JM; Cosgrove SE; Arias CA; Boucher HW; Corey GR; Lowy FD; Murray B; Miller LG; Holland TL;
    Clin Infect Dis; 2017 Mar; 64(suppl_1):S24-S29. PubMed ID: 28350900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): initial results from an international surveillance protocol.
    Jones RN; Fritsche TR; Sader HS; Goldstein BP
    J Chemother; 2005 Dec; 17(6):593-600. PubMed ID: 16433188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distribution of main Gram-positive pathogens causing bloodstream infections in United States and European hospitals during the SENTRY Antimicrobial Surveillance Program (2010-2016): concomitant analysis of oritavancin in vitro activity.
    Mendes RE; Sader HS; Castanheira M; Flamm RK
    J Chemother; 2018 Sep; 30(5):280-289. PubMed ID: 30843778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial Activities of Methanol, Ethanol and Supercritical CO2 Extracts of Philippine Piper betle L. on Clinical Isolates of Gram Positive and Gram Negative Bacteria with Transferable Multiple Drug Resistance.
    Valle DL; Cabrera EC; Puzon JJ; Rivera WL
    PLoS One; 2016; 11(1):e0146349. PubMed ID: 26741962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.